Shockwave Medical Inc (SWAV)
328.87
+0.33
(+0.10%)
USD |
NASDAQ |
Apr 24, 16:00
327.41
-1.46
(-0.44%)
Pre-Market: 09:04
Shockwave Medical SG&A Expense (Quarterly): 92.06M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 92.06M |
September 30, 2023 | 78.36M |
June 30, 2023 | 86.47M |
March 31, 2023 | 73.22M |
December 31, 2022 | 60.38M |
September 30, 2022 | 56.52M |
June 30, 2022 | 53.68M |
March 31, 2022 | 48.35M |
December 31, 2021 | 42.82M |
September 30, 2021 | 37.66M |
June 30, 2021 | 34.34M |
March 31, 2021 | 31.22M |
Date | Value |
---|---|
December 31, 2020 | 23.07M |
September 30, 2020 | 19.23M |
June 30, 2020 | 16.60M |
March 31, 2020 | 16.64M |
December 31, 2019 | 14.05M |
September 30, 2019 | 11.63M |
June 30, 2019 | 10.21M |
March 31, 2019 | 8.872M |
December 31, 2018 | 6.767M |
September 30, 2018 | 6.17M |
June 30, 2018 | 5.764M |
March 31, 2018 | 4.814M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
10.21M
Minimum
Jun 2019
92.06M
Maximum
Dec 2023
42.45M
Average
37.66M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Boston Scientific Corp | 1.379B |
AtriCure Inc | 67.69M |
Masimo Corp | 159.90M |
Perspective Therapeutics Inc | 1.694M |
Xtant Medical Holdings Inc | 20.45M |